Aldoxorubicin hydrochloride NEW
| Price | $57 | $77 | $117 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-05 |
Product Details
| Product Name: Aldoxorubicin hydrochloride | CAS No.: 1361563-03-2 |
| Purity: 100.00% | Supply Ability: 10g |
| Release date: 2025/12/05 |
Product Introduction
Bioactivity
| Name | Aldoxorubicin hydrochloride |
| Description | Aldoxorubicin hydrochloride is an albumin-binding prodrug of Doxorubicin, a DNA topoisomerase II inhibitor. Aldoxorubicin hydrochloride is released from albumin under acidic conditions. Aldoxorubicin hydrochloride exhibits potent antitumor activities in various cancer cell lines and in murine tumor models. |
| In vitro | Aldoxorubicin hydrochloride (0.27 to 2.16 μM) inhibits formation of blood vessel and reduces growth of multiple myeloma cell in a pH-dependent fashion[1]. |
| In vivo | Aldoxorubicin hydrochloride (10.8 mg/kg, i.v.) significantly reduces tumor volumes and IgG levels by day 28, showing high tolerability with a 90% survival rate in mice with LAGκ-1A tumors [1]. It demonstrates a favorable safety profile at doses up to 260 mg/mL doxorubicin equivalents, effectively inducing tumor regression in breast cancer, small cell lung cancer, and sarcoma during a phase I study [2]. Additionally, it outperforms doxorubicin in murine renal cell carcinoma and breast carcinoma xenograft models [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 7.88 mg/mL (10.01 mM), Sonication is recommended. |
| Keywords | topoisomerase II | Aldoxorubicin Hydrochloride | 1361644-26-9 Free base | 1361644-26-9 |
| Inhibitors Related | Ciprofloxacin hydrochloride monohydrate | EIDD-1931 | Levofloxacin hydrochloride | Norfloxacin | Methotrexate disodium | 1,4-Naphthoquinone | Ciprofloxacin monohydrochloride | Ofloxacin | Levofloxacin | Dexamethasone | 3-Hydroxypyridine | Etoposide |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-04 | |
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-19 | |
| $0.00/1kg |
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2022-10-28 | |
| $57.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-05 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY